ImpediMed (IPD) H2 2026 earnings summary

Executive summary

• Revenue increased 15% year-over-year to $14.6 million, with 20% growth in constant currency and 95% U.S. reimbursement coverage for breast cancer-related lymphoedema.

• SOZO® Pro platform expanded into Heart Health and Weight Management, both in early commercial stages.

• Leadership transition: Dr Parmjot Bains stepped down as CEO, succeeded by Erik Anderson in April 2026.

• $15.3 million equity raise completed, $5.0 million used to partially repay debt, and $5.0 million in annualised operating cost reductions implemented.

Financial highlights

• Total revenue: $14.6 million, up 15% from FY25; $15.3 million in constant currency, up 20%.

• Gross margin improved to 87% from 86% in FY25.

• Net loss from operations: $24.9 million, compared to $23.2 million in FY25, mainly due to higher finance expenses.

• Cash and cash equivalents at year-end: $15.3 million (down from $22.2 million in FY25).

• Net cash used in operating activities: $17.9 million (vs. $15.6 million in FY25).

• SOZO Core Business ARR: $14.4 million at 30 June 2026; churn rate 6.8%.

Outlook and guidance

• FY27 priorities: deepen lymphoedema and survivorship platform, drive utilisation and growth in current accounts, scale Heart Health and Weight Management, and progress toward cash flow breakeven.

• Platform positioned for continued growth with expanding clinical guideline support and reimbursement.